This further validates the involvement of the hsa_circ_0008925/SRSF6 signalling pathway in renal fibrosis and suggests that indacaterol may serve as a novel strategy for treating renal fibrosis through the targeting of SRSF6. The gene discussed is SRSF6; the disease is renal fibrosis.